Bicara Therapeutics — Third Quarter 2026 Earnings Summary

Bicara Therapeutics reported a net loss of $71.2 million for the third quarter of 2026, driven by increased research and development expenses related to the FORTIFI-HN01 and FORTIFI-FLEX clinical trials. The company achieved substantial enrollment in the pivotal FORTIFI-HN01 trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, with interim analysis results expected in mid-2027. As of September 30, 2026, Bicara held $442.3 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into the first half of 2029. Additionally, the company plans to present data from its Phase 1b expansion cohort in metastatic colorectal cancer in January 2027 and preclinical fibrosis data in December 2026.